Eris Lifesciences Q4 FY26 profit triples, stock +11%

Key Q4 FY26 results at a glance

Eris Lifesciences reported a three-fold rise in consolidated net profit for Q4 FY26 to ₹281.6 crore. Revenue from operations increased 7.3% year-on-year to ₹756.5 crore. A separate market update pegged the same quarter’s revenue at ₹756.56 crore and net profit at ₹281.61 crore, indicating broadly consistent headline numbers across disclosures. Profit before tax (PBT) was reported at ₹159.41 crore for Q4 FY26, up 23.69% from ₹128.87 crore in Q4 FY25. For the full year FY26, consolidated profit surged 76% to ₹619.5 crore, while revenue from operations grew 8% to ₹3,129.4 crore. Management commentary and presentation excerpts also highlighted domestic formulations strength and stable margins.

Stock reaction during market hours

The results were announced during market hours, and the stock moved sharply. Eris Lifesciences shares rose 11.04% to close at ₹1,484.95 apiece on the BSE. Another intraday data point in the provided text showed the stock up 8.57% to ₹1,455.25 after the earnings release. The price action reflects how quickly markets repriced the quarter’s profit growth and operating performance. Investors also tracked segment updates, especially domestic branded formulations and the insulin franchise. The earnings print arrived alongside margin commentary, which tends to be a key sensitivity for branded formulations players.

Domestic branded formulations led growth

Eris Lifesciences attributed the profit rise primarily to robust domestic performance, though it also flagged that it was on a lower base. In the fourth quarter, the company reported 12% year-on-year growth in its domestic branded formulations (DBF) business revenue. FY26 DBF revenue growth was cited at 11%, underlining the domestic business as the main engine for the year. In management remarks, chairman and managing director Amit Bakshi said domestic formulations posted 11% revenue growth in FY26 along with 12% EBITDA growth. The company also said it maintained an industry-leading EBITDA margin of 37% for domestic formulations.

Margin profile stayed strong

Profitability metrics were a major highlight in the disclosures. Management commentary in the text stated that Q4 domestic business EBITDA grew 10% with a margin of 37%. For the full year, domestic revenue growth was stated at 11% and EBITDA growth at 12%, again with a 37% margin. A separate performance update reported quarterly EBITDA at ₹274 crore in Q4 FY26, up 8% from ₹252 crore in Q4 FY25. That same update pegged EBITDA margin at 36.2% in Q4 FY26 versus 35.8% a year ago. Investor-presentation excerpts also referenced consolidated margin of nearly 36% for the quarter.

Insulin franchise gains were called out

Bakshi said the insulin franchise outpaced market growth fivefold during FY26. The company also reported market share expansion in insulin from 12% to 16% over the year. This detail matters because it links growth to competitive positioning, not only price or base effects. The insulin and anti-diabetes focus also featured in presentation excerpts, where management said it was on track to execute strategic priorities in the anti-diabetes segment. The company’s commentary in the supplied text did not provide separate revenue numbers for insulin, but it clearly highlighted market share momentum.

International business was a drag in Q4

While domestic branded formulations grew, international performance was softer in the quarter. One update in the text said international business fell 8% year-on-year to ₹86 crore in Q4 FY26. Presentation excerpts also noted that exports were “lumpy,” and called this out as one of the factors dragging consolidated growth. The same excerpts flagged trade generics as another element that weighed on the quarter’s growth rate. These points help explain why consolidated revenue growth was in the high-single digits despite stronger domestic execution.

Balance sheet and cash metrics investors tracked

Eris Lifesciences reported net debt of ₹2,255 crore as of March 31, 2026. That balance sheet number is likely to remain in focus for equity investors alongside profit growth and margins. Presentation excerpts included per-share metrics, stating EPS for the quarter came in at around ₹9 and cash EPS at around ₹12. While the article text includes multiple sources and formats, the consistent thread is that profitability and cash generation remain key parts of the investment debate around the company. Management also referenced confirmed contracts of more than ₹100 crore of revenue per annum that are in various stages of execution, indicating visibility in parts of the business.

Interim dividend announced: record date and payout timeline

Alongside earnings, the company declared an interim dividend of ₹7.21 per fully paid-up equity share of face value ₹1 for FY27. The record date was fixed as Friday, May 29, 2026, to determine shareholder eligibility. The dividend is scheduled to be paid on or before June 19, 2026. For income-focused investors, these dates matter as much as the headline dividend number. The announcement also signals management confidence, although the text does not provide a stated payout ratio or dividend policy update.

Key numbers table: Q4 and FY26 snapshot

The disclosures provided several headline numbers for Q4 FY26 and FY26, plus select segment indicators. Where multiple figures appeared for the same line item (for example, consolidated revenue), the table uses the values explicitly stated in the news copy and market update. Investors typically read these alongside segment commentary on domestic branded formulations and exports. The company’s narrative stressed strong domestic execution and stable margins, while acknowledging lumpiness in exports.

What investors may watch after the results

Management commentary in the supplied text pointed to execution priorities across anti-diabetes, the base business, and international operations. It also flagged exports as lumpy, which can keep quarter-to-quarter comparisons uneven. The confirmed contracts of more than ₹100 crore of revenue per annum, described as being in various stages of execution, is another datapoint investors may track in subsequent updates. With domestic formulations growing in double digits and margins described as strong, future commentary on mix, exports, and debt levels is likely to remain central to market discussions. Any further disclosures on how the insulin franchise growth translates into revenue and profitability would also be closely followed, but the provided text does not quantify that within Q4/FY26 financials.